IP Library Granted Patent US 7,960,579
Granted Patent B2
US 7,960,579 · App. 10/562,018 · Granted Jun 14, 2011

2-amino-bicyclo [3.1.0] hexane-2,6-dicarboxylic ester derivative

Assignee: Taisho Pharmaceutical Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,960,579
App. No.
10/562,018
Granted
Jun 14, 2011
Kind
B2
Abstract

A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administration A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I] [wherein R 1 and R 2 are identical or different, and each represents a hydrogen atom, a C 1-10 alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR 3 R 4 or the like (wherein R 3 and R 4 are identical or different, and each represents a hydrogen atom, a C 1-10 alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.

Claims (18)

1. (1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 6-methyl ester represented by the following structure:

2. (1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 6-n-propyl ester represented by the following structure:

3. (1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 6-iso-propyl ester represented by the following structure:

4. (1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 6-n-butyl ester represented by the following structure:

5. (1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 6-(2-methylpropyl) ester represented by the following structure:

6. (1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 6-n-pentyl ester represented by the following structure:

7. (1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 6-n-decyl ester represented by the following structure:

8. (1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 6-cyclohexyl ester represented by the following structure:

9. (1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 6-cyclohexylmethyl ester represented by the following structure:

10. (1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 6-(3-methylbutyl) ester represented by the following structure:

11. (1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 6-n-hexyl ester represented by the following structure:

12. (1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 6-(4-methylpentyl) ester represented by the following structure:

13. (1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 6-(2-ethylbutyl) ester represented by the following structure:

14. (1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 6-n-heptyl ester represented by the following structure:

15. (1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 6-(5-methylhexyl) ester represented by the following structure:

16. (1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 6-n-octyl ester represented by the following structure:

17. (1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 6-(6-methylheptyl) ester represented by the following structure:

18. (1R,2R,3R,5R,6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 6-n-nonyl ester represented by the following structure:

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2006
From: YASUHARA, AKITO; SAKAGAMI, KAZUNARI; OHTA, HIROSHI; NAKAZATO, ATSURO
To: TAISHO PHARMACEUTICAL CO., LTD.
Reel/Frame 018324/0626 →
Priority Claims (3)
JP 2003-181930 · Jun 26, 2003 · national
JP 2003-373511 · Oct 31, 2003 · national
JP 2004-128663 · Apr 23, 2004 · national
Continuity (1)
Related Publication 20070021394A1 · Jan 25, 2007